Praxis Precision Medicines, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Praxis is a clinical-stage biopharmaceutical company developing CNS therapies through its Cerebrum small-molecule and Solidus antisense oligonucleotide platforms. It had no product sales; reported revenue was collaboration revenue.
Financial results and liquidity
- Q2 revenue: $0.8 million, all from the UCB research collaboration, versus none in Q2 2022. First-half revenue: $1.5 million.
- Q2 net loss: $34.3 million ($0.49 per share), compared with $60.2 million ($1.32 per share) in Q2 2022. First-half net loss: $71.8 million ($1.17 per share), versus $128.9 million ($2.83 per share) in 2022.
- Operating expenses: Q2 research and development (R&D) was $25.6 million and general and administrative (G&A) was $10.1 million; first-half R&D was $51.1 million and G&A was $23.4 million. The filing does not present a meaningful gross margin for this pre-commercial business.
- Cash flow: First-half net cash used in operating activities was $64.1 million, versus $111.3 million in 2022. Investing activities provided $39.0 million, mainly from marketable-security maturities; financing activities provided $87.7 million, mainly from equity offerings.
- Liquidity and balance sheet: At June 30, cash and cash equivalents were $124.3 million, with no marketable securities; current assets were $129.8 million and current liabilities $24.4 million. Total liabilities were $27.9 million, including lease and deferred-revenue liabilities; the filing reports no debt balance. Accumulated deficit was $602.4 million.
- Management said cash at June 30 was expected to fund operations and capital needs into the first quarter of 2025 under its current plan, which limits programs to their current trials and ulixacaltamide’s planned Phase 3 trials. The going-concern discussion separately states cash is expected to cover at least one year from issuance. Both assessments depend on assumptions and do not assure funding beyond those plans.
Changes versus prior year and notable items
- Q2 operating expenses fell $24.7 million year over year and first-half expenses fell $54.7 million; net losses narrowed accordingly. The principal driver was lower Cerebrum spending, including reduced PRAX-114 activity after the 2022 strategic realignment and lower prior-period manufacturing and trial costs. Reduced headcount also lowered personnel and G&A costs.
- Solidus R&D increased, including a $6.9 million Ionis milestone accrued when the PRAX-222 EMBRAVE study began; the milestone was paid in July 2023.
- Praxis raised approximately $63.4 million net in a June follow-on offering of common stock and pre-funded warrants, and $24.1 million net from at-the-market sales during the first half. The June offering included 64.45 million common shares and warrants for 7.05 million additional shares. Common shares issued and outstanding rose to 128.54 million at quarter-end from 49.38 million at year-end 2022. The pre-funded warrants remained outstanding at June 30 and may be exercised for nominal consideration, creating potential dilution.
- There was no material legal proceeding reported, and management reported disclosure controls and procedures were effective as of June 30.
Outlook, development plans, and risks
- Management planned to start two ulixacaltamide Phase 3 studies for essential tremor in Q4 2023, with topline results expected in the second half of 2024. The filing notes Phase 2b Essential1 topline results had been announced in Q1 2023.
- PRAX-562’s Phase 2 EMBOLD study was underway, with topline results expected in Q4 2023. PRAX-628’s Phase 2 photo-paroxysmal-response study began in June, with results anticipated by year-end 2023; a focal-epilepsy Phase 2 study was planned for the first half of 2024. PRAX-222’s first EMBRAVE dose cohort began in Q2, with topline results expected in the second half of 2023.
- The company expects continuing operating losses and negative operating cash flows, and says substantial additional funding will be needed. It had no committed external funding source. If financing or collaborations are unavailable on acceptable terms, Praxis may delay, reduce, or stop programs; equity financing could dilute shareholders, while collaborations may require giving up rights.
- Key risks include clinical efficacy, safety, enrollment and timing; regulatory approval; manufacturing and third-party performance; intellectual-property protection and licensing; competition; and the ability to raise capital. Timelines and funding estimates are forward-looking and subject to change.
Important facts for investors to verify
- Whether clinical milestones and stated topline-result timelines are achieved, and what the data show on efficacy and safety.
- Whether the cash runway remains consistent with management’s assumptions as trial scope and spending evolve; reconcile the stated first-quarter 2025 outlook with the more limited one-year liquidity assessment.
- Potential dilution from the 7.05 million pre-funded warrants, outstanding options and future equity needs.
- UCB collaboration economics and progress: the filing cites up to $98.5 million in potential option and success-based milestones plus tiered royalties, all dependent on future events.